ASH: Novo’s Etavopivat For Sickle Cell Disease Cuts VOC Rates In Half

Phase III Ongoing, Endpoints Under Discussion With Regulators

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.